According to the Institute of Medicine (US), 100 million American adults are affected by chronic pain, higher than the combined total number of people effected by cancer, diabetes, and heart disease. Pain can affect in one’s body functioning even while performing the simplest activities. Neuromodulation has helped patients recover completely from these chronic pains and resume their routine lives. There are multiple types of neuromodulations that can be used such as spinal drug delivery systems, spinal cord stimulation, brain stimulation, sacral stimulation, peripheral nerve stimulation and peripheral nerve field stimulation. Many research and clinical trials have published promising papers proving the ability and safety of neuromodulation devices to improve quality of life of patients. The nervous system’s electrical properties were discovered more than a hundred years ago, however, they have only been harnessed for treatments recently. First cochlear implants, enhancing patients’ awareness of the environment and aid them with lip reading were invented in 1970s.

Also Read: http://www.marketwatch.com/story/neuromodulation-devices-market-res...
Based on technology the neuromodulation devices market is divided into spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, transcranial magnetic stimulators, and others. Spinal cord stimulators segment is expected to witness highest CAGR growth during the forecast period. Neuromodulation devices have grown at their highest in the last decade, with novel chronic pain indications, hardware advancements and waveforms. In 2021, Medtronic announced the FDA has approved its recharge-free neurostimulator for spinal cord stimulation, Vanta. In the same year, CVRx filed paperwork to hold an IOP to raise up to US$75 million to commercialize its neurostimulator for heart failure. Spinal cord stimulation (SCS) is used in many refractory chronic pain conditions like complex regional pain syndrome, failed back surgery syndrome, angina pectoris, abdominal pain, and ischemic limb pain.

Also Read: http://www.marketwatch.com/story/multiple-specialty-oils-market-res...
Based on application, neuromodulation devices market is segmented into pain management, hearing loss, depression, parkinson’s disease, epilepsy, and others. Pain management is expected to witness highest CAGR growth during the forecast period. Neuromodulation tools can increase or decrease the activity in the nervous system. This technology can be effective in reducing many nervous system related diseases, pain, hearing, epilepsy etc. According to WHO, there are currently 264 million people suffering from depression in 2020 and 50 million people suffering from epilepsy (2019) worldwide. Additionally, the national institutes of health in 2020 published that, 1 in 5 people in the United States suffer from chronic pain. Recent advancements in cochlear implants have enabled people to hear and understand speech. Cochlear implants save US$ 30,000-50,000 per person over their lifetimes. More than 100,000 parkinson’s patients have been implanted with Deep brain stimulation (DBS). This is better than drug therapy, which causes unpleasant side-effects. DBS can reduce the patient’s reliance on drugs and lessen their side effects by up to 44%.

Also Read: http://www.marketwatch.com/story/pvc-plasticizer-global-market-insi...
For a better understanding of the market and the device adoption, the report provides detailed analysis for major regions including North America (US, Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, UK and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a major market for the neuromodulation devices industry and generated revenue of US$ XX billion in 2020 owing to the increasing incidence of neurological diseases. Some of the major players operating in the market include Abbott Laboratories, Boston Scientific Corporation, Medtronic PLC, Nevro Corporation, St. Jude Medical, Inc., Neurosigma Inc., Neuronetics Inc., LivaNova PLC, Nuvectra, Cyberonics. Several M&A’s along with partnerships have been undertaken by these players to develop neuromodulation devices.

Table Of Contain:

1 MARKET INTRODUCTION
1.1 Market Definitions
1.2 Objective of the Study
1.3 Limitation
1.4 Stake Holders
1.5 Currency Used in Report
1.6 Scope of the Neuromodulation Devices Market Study
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1 Research Methodology for the Neuromodulation Devices Market
2.1.1 Main Objective of the Neuromodulation Devices Market
3 INDUSTRY PERFORMANCE
4 EXECUTIVE SUMMARY
5 COVID-19 IMPACT
6 MARKET INSIGHTS BY TECHNOLOGY
6.1 Spinal Cord Stimulators
6.2 Deep Brain Stimulators
6.3 Sacral Nerve Stimulators
6.4 Vagus Nerve Stimulators
6.5 Transcranial Magnetic Stimulators
6.6 Others
7 MARKET INSIGHTS BY APPLICATION
7.1 Pain Management
7.2 Hearing Loss
7.3 Depression
7.4 Parkinson's Disease
7.5 Epilepsy
7.6 Others
8 MARKET INSIGHTS BY REGION
8.1 NORTH AMERICA NEUROMODULATION DEVICES MARKET
8.1.1 United States of America
8.1.2 Canada
8.1.3 Rest of North America
8.2 EUROPE NEUROMODULATION DEVICES MARKET
8.2.1 United Kingdom
8.2.2 Germany
8.2.3 France
8.2.4 Spain
8.2.5 Italy
8.2.6 Rest of Europe
8.3 ASIA-PACIFIC NEUROMODULATION DEVICES MARKET
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 Australia
8.3.5 Rest of Asia-Pacific
8.4 REST OF THE WORLD NEUROMODULATION DEVICES MARKET
9 LEGAL AND REGULATORY FRAMEWORK
10 DEMAND AND SUPPLY SIDE ANALYSIS
10.1 Demand Side Analysis
10.2 Supply Side Analysis
10.2.1 Top Product Launches
10.2.2 Top Business Partnerships
10.2.3 Top Business Expansions, Investments and Divestitures
10.2.4 Top Merger and Acquisitions
11 VALUE CHAIN ANALYSIS
12 NEUROMODULATION DEVICES MARKET TRENDS & INSIGHTS
13 NEUROMODULATION DEVICES MARKET DYNAMICS
13.1 Drivers
13.2 Challenges
13.3 Impact Analysis
13.4 Opportunity
14 COMPETITIVE SCENARIO
14.1 Neuromodulation Devices Market Share, by Company 2020
15 COMPANY PROFILED
15.1 Abbott Laboratories
15.2 Boston Scientific Corporation
15.3 Medtronic PLC
15.4 Nevro Corporation
15.5 St. Jude Medical, Inc.
15.6 Neurosigma Inc.
15.7 Neuronetics Inc.
15.8 LivaNova PLC
15.9 Nuvectra
15.10 Cyberonics
16 DISCLAIMER ----

…….Continued

CONTACT DETAILS :

[email protected]

+44 203 500 2763

+1 62 825 80070

971 0503084105